Pharmaco-Economics: The Cost of Health

Pharmaco-Economics: The Cost of Health

AK Mohiuddin

Department of Pharmacy, World University of Bangladesh, Bangladesh 151/8, Green Road Dhanmondi, Dhaka – 1205, Bangladesh

American journal of educational research and reviews

Pharmacoeconomics has been characterized as the depiction and examination of the cost of medication treatment to healthcare frameworks and society. All the more explicitly, pharmacoeconomic look into is the way toward recognizing, estimating, and contrasting the costs, dangers, and advantages of programs, services, or treatments and figuring out which elective delivers the best wellbeing result for the asset contributed. This data can help clinical chiefs in picking the most cost-effective treatment alternatives. Pharmacoeconomics is a division of results examine that can be utilized to measure the estimation of pharmaceutical care items and services. Pharmaceutical care has been characterized as the mindful arrangement of medication treatment for the reasons for accomplishing unequivocal results.
Purpose of the study: Discussion and projection about pharmacoeconomics.
Findings: Cost of therapy is always been a concern for health seeking behavior of every country from both developed and underprivileged communities. Several cost calculations impose economic burden statistics and pharmacoeconomics deal with them. Pharmacists and other healthcare associates have much scope to contribute regarding cost minimization.
Materials and Methods: Research conducted a year-round comprehensive literature search, which included technical newsletters, newspapers journals, and many other sources. The present study was started from the beginning of 2018. PubMed, ALTAVISTA, Embase, Scopus, Web of Science, and the Cochrane Central Register of was thoroughly searched. The keywords were used to search for different publishers’ journals like Elsevier, Springer, Willey Online Library, Wolters Kluwer were extensively followed. Medicine and technical experts, pharma company representatives, hospital nurses and chemists were given their valuable suggestions. Projections were based on estimates of drug and therapy related cost, cost of being ill and hospitalization and cost of well-being. Pharmacists role in allied areas of cost calculation and minimizing through ADR management, prevent disease and hospitalization and drug selection were given the highest priority.

Keywords: Pharmacists; Healthcare expenditure; Hospitalization; Medication; Cost; Outcomes

Free Full-text PDF

How to cite this article:
AK Mohiuddin, Pharmaco-Economics: The Cost of Health. International Journal of Marketing Research, 2019,1:1.

1. Centers for Medicare & Medicaid Service (CMS). National Health Expenditure Data. Available From:
2. Vogenberg FR, Santilli J. Healthcare Trends for 2018. Am Health Drug Benefits. 2018;11(1):48-54.
3. Gattani SG, Patil AB, Kushare SS. Pharmacoeconomics: A Review. Asian Journal of Pharmaceutical and Clinical Research Vol.2 Issue 3, July -September 2009
4. Lisa Sanchez Trask Access Pharmacy Chapter 1. Pharmacoeconomics: Principles, Methods, and Applications
5. P. V. Powar, et al (2014), Pharmacoeconomics – Costs of Drug Therapy to Healthcare Systems. J. of Modern Drug Discovery And Drug Delivery Research. V1I2. Available From:
6. Kozma C. Reeder CE. Schulz RM. Economic, clinical, and humanistic outcomes: A planning model for pharmacoeconomic research. Clinical Therapeutics 15(6):1121-32; discussion 1120.
7. Telser H, Fischer B, Leukert K, Vaterlaus S. Healthcare expenditure and illness-related costs. In InterPharmaPh Polynomics. Published by: Interpharma, Association of research-based pharmaceutical companies in Switzerland, Basel © Interpharma/Polynomics, September 2011.
8. Babigumira JB. Types of Economic Evaluation in Healthcare. Global Medicines Program Department of Global Health by Center for AIDS Research.
9. 2 Economic Valuation of Life and Health – Springer
10. Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014 Dec;20(4):327-37. doi: 10.3350/cmh.2014.20.4.327. Epub 2014 Dec 24. Review. PubMed PMID: 25548737; PubMed Central PMCID: PMC4278062.
11. Applying Principles of Pharmacoeconomics to Improve Medical Product Selection and Use in Low- and Middle-income Countries: Trainer’s Guide August 2017.
12. Access Pharmacy Mc-Graw Hill Medical. Chapter 9. Principles of Pharmacoeconomics. Available From:
13. Surji KM. Fundamental Understanding of Pharmacoeconomics as an Innovative Concept within the Modern Clinical Pharmacy in Today’s Healthcare System American Journal of Pharmacy and Health Research 2015, Volume 3, Issue 5, ISSN: 2321–3647
14. Dubois DJ. Grand challenges in pharmacoeconomics and health outcomes. Front Pharmacol. 2010;1:7. Published 2010 Jun 23. doi:10.3389/fphar.2010.00007
15. Ambrosioni E. Pharmacoeconomic challenges in disease management of hypertension. J Hypertens Suppl. 2001 Sep;19(3):S33-40. Review. PubMed PMID: 11713849.
16. Chabot I, LeLorier J, Blackstein ME. The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour. Eur J Cancer. 2008 May;44(7):972-7. doi: 10.1016/j.ejca.2008.02.041. Epub 2008 Mar 26. PubMed PMID: 18372169.
17. Catić T, Skrbo S. Pharmacoeconomic education for pharmacy students in bosnia and herzegovina. Mater Sociomed. 2013;25(4):282-5.
18. Milne RJ. Evaluation of the pharmacoeconomic literature. Pharmacoeconomics. 1994 Oct;6(4):337-45. PubMed PMID: 10147470.
19. Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327-37.
20. Scaria S, Raju R, Joseph S, Mohan A, Nair AA. Pharmacoeconomics: Principles, Methods and Indian Scenario International Journal of Pharmaceutical Sciences Review and Research 34(1), September October 2015; Article No. 08, Pages: 37-46 ISSN 0976 –044X
21. Ahmad A, Patel I, Parimilakrishnan S, Mohanta GP, Chung HC, Chang J. The role of pharmacoeconomics in current Indian healthcare system Journal of Research in Pharmacy Practice 2013 Jan-Mar; 2(1): 3–9. DOI: 10.4103/2279-042X.114081 PMID: 24991597
22. Bootman JL, Townsend RJ, McGham WF. Principles of Pharmacoeconomics, Chapter 1, Introduction to Pharmacoeconomics. Available from:
23. Pharmacoeconomics: Evaluation methods Available From:
24. Canadian Coordinating Office for Health Technology Assessment. Guidelines For Economic Evaluation Of Pharmaceuticals: Canada Available From:
25. Parkis R. Pharmacoeconomics – the importance for pharmacists. The Pharmaceutical Journal FEB 2006. Available From:
26. Gyllensten H, Hakkarainen KM, Hägg S, et al. Economic impact of adverse drug events–a retrospective population-based cohort study of 4970 adults. PLoS One. 2014;9(3):e92061. Published 2014 Mar 17. doi:10.1371/journal.pone.0092061
27. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci. 2002;24(2):46–54.
28. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med. 2008;168(17):1890–1896.
29. Sawyer RT, Odom JM, Jennings J, Orr J, Cass AL. Discharge medication reconciliation by pharmacists to improve transitions following hospitalization (DEPTH) 2016. Available from:
30. Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004;291(21):2616–2622.
31. Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition: multimorbidity. JAMA. 2012;307(23):2493–2494.
32. Bunting BA, Smith BH, Sutherland SE. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc (2003) 2008;48(1):23–31.
33. Khdour MR, Kidney JC, Smyth BM, McElnay JC. Clinical pharmacyled disease and medicine management programme for patients with COPD. Br J Clin Pharmacol. 2009;68(4):588–598.
34. Morello CM, Zadvorny EB, Cording MA, Suemoto RT, Skog J, Harari A. Development and clinical outcomes of pharmacist-managed diabetes care clinics. Am J Health Syst Pharm. 2006;63(14):1325–1331.
35. Hall D, Buchanan J, Helms B, et al. Health care expenditures and therapeutic outcomes of a pharmacist-managed anticoagulation service versus usual medical care. Pharmacotherapy. 2011;31(7):686–694.
36. Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8(1):e016982. Published 2018 Jan 21. doi:10.1136/bmjopen-2017-016982
37. Rotta I, Salgado TM, Silva ML, Correr CJ, Fernandez-Llimos F. Effectiveness of clinical pharmacy services: an overview of systematic reviews (2000-2010) Int J Clin Pharm. 2015;37(5):687–697.
38. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296(21):2563–2571.
39. Centers for Medicare and Medicaid Services, editor. NHE Projections 2010–2020. Washington, DC: US Department of Health and Human Services; 2011
40. Kaiser Family Foundation, editor. Health care costs: a primer. Available from:
41. Bekker CL, Gardarsdottir H, Egberts ACG, Bouvy ML, van den Bemt BJF. Pharmacists’ Activities to Reduce Medication Waste: An International Survey. Pharmacy (Basel). 2018;6(3):94. Published 2018 Aug 29. doi:10.3390/pharmacy6030094
42. Usherwood T. Encouraging adherence to long-term medication. Aust Prescr. 2017;40(4):147-150.
43. The US Department of Treasury, editor. The 2012 annual report of the boards of trustees of the federal hospital insurance and federal supplementary medical insurance trust funds. 2012. Available from:
44. IMS Institute for Healthcare Informatics. Global Medicines use in 2020: Outlook and Implications. IMS Institute, Parsippany, New Jersey. 2015. Accessed 3 May 2016.
45. Wheeler AJ, Spinks J, Bettington E, Kelly F. Evaluation of the National Return of unwanted medicines (RUM) program in Australia: a study protocol. J Pharm Policy Pract. 2017;10:38. Published 2017 Dec 7. doi:10.1186/s40545-017-0126-6
46. Bettington E, Spinks J, Kelly F, Wheeler AJ. Returning unwanted medicines to pharmacies: prescribing to reduce waste. Aust Prescr. 2018;41(3):78-81.
47. James TH, Helms ML, Braund R. Analysis of medications returned to community pharmacies. Ann Pharmacother. 2009 Oct;43(10):1631-5. doi: 10.1345/aph.1M209. Epub 2009 Sep 23. PubMed PMID: 19776296.
48. Latif A. Community pharmacy Medicines Use Review: current challenges. Integr Pharm Res Pract. 2018;7:83-92. Published 2018 Jul 9. doi:10.2147/IPRP.S148765
49. United-Kingdom Department of Health: Choosing health through pharmacy–a programme for pharmaceutical public health 2005–2015.
50. Pharmaceutical Service Negotiating committee. NHS community pharmacy contractual framework enhanced service: minor ailment service. 2005; pp 9–11.
51. Auta A, Maz J, Strickland-Hodge B. Perceived facilitators to change in hospital pharmacy practice in England. Int J Clin Pharm. 2015;37(6):1068–1075.
52. Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: current insights. Integr Pharm Res Pract. 2017;6:37-46. Published 2017 Jan 25. doi:10.2147/IPRP.S108047
53. Sawyer RT, Odom JM, Jennings J, Orr J, Cass AL. Discharge medication reconciliation by pharmacists to improve transitions following hospitalization (DEPTH) 2016. [Accessed December 16, 2016]. Available from:

Terms of Use/Privacy Policy/ Disclaimer/ Other Policies:
You agree that by using our site, you have read, understood, and agreed to be bound by all of our terms of use/privacy policy/ disclaimer/ other policies (click here for details).

This work and its PDF file(s) are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.